<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-RIL25863-KMN-HY-3NT"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S2561 IS: Skin Substitute Access and Payment Reform Act of 2025</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-07-31</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 2561</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250731">July 31, 2025</action-date><action-desc><sponsor name-id="S373">Mr. Cassidy</sponsor> introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend title XVIII of the Social Security Act to reform the payment rules regarding skin substitute products.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Skin Substitute Access and Payment Reform Act of 2025</short-title></quote>.</text></section><section commented="no" display-inline="no-display-inline" id="id3ebee7b55e084df39bb4bdd52b771abc" section-type="subsequent-section"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text><paragraph id="idcfaff2ca65484b599e2bb63f098ef3e9"><enum>(1)</enum><text>Skin substitute products are advanced biological therapies used to treat chronic, non-healing wounds, such as diabetic foot ulcers and venous leg ulcers. Each year, more than 10,500,000 Medicare beneficiaries will require medical care for treatment of a wound. By improving healing rates and reducing the rate of lower limb amputation, skin substitute products improve the health and wellness of Medicare beneficiaries.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id0641fe12b1d849bbbcb1a5666a313410"><enum>(2)</enum><text>These treatments vary in makeup and source material, including human tissue-derived products, non-human, animal-derived products, and synthetic products. Studies show that different skin substitute products are similarly safe and effective in treating chronic wounds, and Medicare coverage does not currently differentiate between different types of lawfully marketed skin substitutes. Healthcare providers are well-informed about alternative skin substitute products and are in the best position to determine which specific product would best suit each specific patient based on the patient’s specific needs and the provider’s knowledge and experience.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id554277976e9b431a92b302f356b8454a"><enum>(3)</enum><text>The Centers for Medicare &amp; Medicaid Services has faced challenges in determining consistent and accurate pricing and payment for services that involve skin substitute products, resulting in uncertainty and significant price differences among these products.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id6f16ca6436c442be8c8b828f309a2d61"><enum>(4)</enum><text>The Medicare payment systems in place at the date of enactment of this Act incentivize use of more expensive products and continued price increases while failing to recognize the similar clinical effects of skin substitute products. Medicare expenditures for skin substitute products rose significantly in 2024 and 2025.</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id829bf553d5194631bc7ee6ab84596dae"><enum>(5)</enum><text>It is therefore necessary to reform the Medicare payment and coverage rules for skin substitute products to appropriately recognize the well-established and known clinical value of these treatments while containing costs.</text></paragraph></section><section commented="no" display-inline="no-display-inline" id="idcb65f4a98c42427597119538ff9115b8"><enum>3.</enum><header>Payment reform for skin substitute products</header><subsection commented="no" display-inline="no-display-inline" id="idb30b1f2d3f4245fca65c97c481f25130"><enum>(a)</enum><header>In general</header><text>Section 1847A(b) of the Social Security Act (42 U.S.C. 1395w–3a(b)) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="id22b360c309994efbaf8bc3b77e3664a0"><enum>(1)</enum><text>in paragraph (1)—</text><subparagraph commented="no" display-inline="no-display-inline" id="idaf5b4a9adca043d08549af8b2f0183b2"><enum>(A)</enum><text display-inline="yes-display-inline">subparagraph (B), by striking <quote>or</quote> at the end;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc357dc8d00704068b75b9ea16affcd93"><enum>(B)</enum><text>in subparagraph (C), by striking the period at the end and inserting <quote>; or</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id5d8e24b76026475d9787fa2c646ea057"><enum>(C)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id1426d614c7544f7f92df8a02f4fbdc12"><subparagraph commented="no" display-inline="no-display-inline" id="id0429941b632048c1a7abf9b187403dd8"><enum>(D)</enum><text>in the case of a skin substitute product (as defined in subsection (c)(6)(J)), the amount determined under paragraph (9).</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id4f1305dbd31d49e795f65b5c0f017a18"><enum>(2)</enum><text display-inline="yes-display-inline">by adding at the end the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id844dcbd7c69c48499d73b262fe717215"><paragraph commented="no" display-inline="no-display-inline" id="id23ee8ab52b2041beb99ea18840582497"><enum>(9)</enum><header>Skin substitute products</header><subparagraph commented="no" display-inline="no-display-inline" id="id7d7ac1e09ade4b01aa33171e8eb290f6"><enum>(A)</enum><header>In general</header><text>Beginning on January 1, 2026, for any skin substitute product (as defined in subsection (c)(6)), the amount specified in this paragraph is the volume-weighted average of the payment allowance limit calculated under subparagraph (B).</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id5598eeb7d81c40e09b2581a51f5afa73"><enum>(B)</enum><header>Volume-weighted average payment limit</header><text>The volume-weighted average of the payment allowance limit of a skin substitute product under this paragraph is determined by—</text><clause commented="no" display-inline="no-display-inline" id="id2f41a841bc154b13be5d04647c70a467"><enum>(i)</enum><text>calculating the sum of the products of—</text><subclause commented="no" display-inline="no-display-inline" id="id8c8d3cad922e40af987363024ad6c127"><enum>(I)</enum><text>the published payment allowance limit for each billing and payment code listed in the ASP Pricing File published by the Secretary for the fourth calendar quarter of 2023 for each skin substitute product; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id7b74b80ccc394eb1a8b3c1a700035f00"><enum>(II)</enum><text>the total number of units, as specified under paragraph (2), for each billing and payment code described in subclause (I), billed with dates of service from October 1, 2023, to December 31, 2023, and listed in the Integrated Data Repository for Part B claims data; and</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="id34cec94bd9e34c9a9bfece05fbff99da"><enum>(ii)</enum><text>dividing the sum calculated under clause (i) by the total number of units under subclause (II).</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id2200c76f1c0b41e893c717c7ba316864"><enum>(C)</enum><header>Updates to payment amounts</header><text display-inline="yes-display-inline">For 2027 and each subsequent year, the amount specified in this paragraph shall be adjusted for the percentage increase in the consumer price index for all urban consumers (U.S. city average) for the 12-month period ending with June of the previous year.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id01ee2e29274741b6b1bd154d17835008"><enum>(b)</enum><header>Definition and other rules for skin substitute products</header><text>Section 1847A(c)(6) of the Social Security Act (42 U.S.C. 1395w–3a(c)(6)) is amended by adding at the end the following new subparagraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="ide73a4c2c0cf14b1d8475ed38a19b8df3"><subparagraph commented="no" display-inline="no-display-inline" id="id64c4e986b96b42ed92a355ac2075b598"><enum>(J)</enum><header>Skin substitute products</header><clause id="id5483e21481a94d7e81cdf22ac72719df"><enum>(i)</enum><header>In general</header><text>The term <term>skin substitute product</term>—</text><subclause commented="no" display-inline="no-display-inline" id="ide018f8759c05485eab0fb66dfd276893"><enum>(I)</enum><text display-inline="yes-display-inline">means a cellular, biological or synthetic material or tissue applied to a wound and intended to remain within the wound bed, including a product approved, cleared, or authorized to section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(k)</external-xref>, 260c(f)(2), 360e) or section 361 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/264">42 U.S.C. 264</external-xref>), and their implementing regulations; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="idcb2487858fea4aa2aa5dceec969b8e1f"><enum>(II)</enum><text>does not include—</text><item commented="no" display-inline="no-display-inline" id="idbbf9f90667124502b961a8e825d94b07"><enum>(aa)</enum><text>any product that is intended to temporarily protect or cover the wound bed and be removed before complete resorption, such as a dressing;</text></item><item commented="no" display-inline="no-display-inline" id="id1b6ccc1f10494dbbbfebfeab50cc68be"><enum>(bb)</enum><text>any liquid, gel, powder, or other similarly constituted item; or</text></item><item commented="no" display-inline="no-display-inline" id="id6f9f878676b745e1b6c504f122f4d5a6"><enum>(cc)</enum><text>any product that would otherwise meet the requirements of subclause (I), but is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or licensed under section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)</external-xref>).</text></item></subclause></clause><clause commented="no" display-inline="no-display-inline" id="iddb1670af94a440ac9a6a4369536934a9"><enum>(ii)</enum><header>Consolidated billing and payment code</header><text display-inline="yes-display-inline">Not later than January 1, 2026, the Secretary shall establish a new billing and payment code for all skin substitute products.</text></clause><clause commented="no" display-inline="no-display-inline" id="idb7d8343f64da47b99b4600ab3b29a932"><enum>(iii)</enum><header>Special rules</header><text>Beginning on January 1, 2026, the following rules shall apply:</text><subclause commented="no" display-inline="no-display-inline" id="id8e8b209c20ed4553afc5808c319fa495"><enum>(I)</enum><text display-inline="yes-display-inline">Each skin substitute product shall be subject to the same criteria when determining whether such skin substitute product is reasonable and necessary for the diagnosis or treatment of illness or injury under section 1862(a)(1)(A), unless determined by the Secretary that such product is unsafe based on evidence of contamination, serious infectious disease, or serious adverse reactions caused by such product.</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id767e6f5782504bd7ba0ca86117b22830"><enum>(II)</enum><text display-inline="yes-display-inline">The Secretary may not determine that a skin substitute product is not considered reasonable and necessary for the diagnosis or treatment of illness or injury under section 1862(a)(1)(A) based solely on analysis of any clinical evidence relating to such product.</text></subclause><subclause commented="no" display-inline="no-display-inline" id="idb8e638a22e334e63a222faecbc1b0ab3"><enum>(III)</enum><text display-inline="yes-display-inline">A manufacturer of a skin substitute product shall not be required to report the average sales price for such product under section 1927(b)(3)(A)(iii) or subsection (f)(2).</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></legis-body></bill>

